REVELATION BIOSCIENCES INC

For the period ended Dec 31, 2023. Filed Mar 22, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 22, 2024

REVB$4.11+5.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,2023	December 31,2022
ASSETS
Current assets:
Cash and cash equivalents	$11,991,701	$5,252,979
Deferred offering costs	71,133	87,171
Prepaid expenses and other current assets	84,691	73,132
Total current assets	12,147,525	5,413,282
Property and equipment, net	65,084	90,133
Total assets	$12,212,609	$5,503,415
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$1,359,898	$554,205
Accrued expenses	1,152,460	985,497
Deferred underwriting commissions	2,911,260	2,911,260
Warrant liability	141,276	—
Total current liabilities	5,564,894	4,450,962
Total liabilities	5,564,894	4,450,962
Commitments and Contingencies (Note 4)
Stockholders’ equity:
Series A Preferred Stock, $0.001 par value; zero and one shares authorized, issued and outstanding at December 31, 2023 and December 31, 2022, respectively; liquidation preference of $0 and $5,000 at December 31, 2023 and December 31, 2022, respectively	—	—
Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022 and 264,537 and 77,375 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	265	77
Additional paid-in-capital	32,114,552	26,399,224
Accumulated deficit	(25,467,102)	(25,346,848)
Total stockholders’ equity	6,647,715	1,052,453
Total liabilities and stockholders’ equity	$12,212,609	$5,503,415

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.